Author/Authors :
Xavier Barril، نويسنده , , Mandy C. Beswick، نويسنده , , Adam Collier، نويسنده , , Martin J. Drysdale، نويسنده , , Brian W. Dymock، نويسنده , , Alexandra Fink، نويسنده , , Kate Grant، نويسنده , , Robert Howes، نويسنده , , Allan M. Jordan، نويسنده , , Andrew Massey، نويسنده , , Allan Surgenor، نويسنده , , Joanne Wayne، نويسنده , , Paul Workman، نويسنده , , Lisa Wright، نويسنده ,
Abstract :
Novel piperazinyl, morpholino and piperidyl derivatives of the pyrazole-based Hsp90 inhibitor CCT018159 are described. Structure–activity relationships have been elucidated by X-ray co-crystal analysis of the new compounds bound to the N-terminal domain of human Hsp90. Key features of the binding mode are essentially identical to the recently reported potent analogue VER-49009. The most potent of the new compounds has a methylsulfonylbenzyl substituent appended to the piperazine nitrogen, possesses an IC50 of less than 600 nM binding against the enzyme and demonstrates low micromolar inhibition of tumour cell proliferation.
Keywords :
HSP90 , cancer , structure-based drug design , Pyrazole , X-ray crystallography